Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Hydrogen in Autoimmune Diseases
NCT05116215Phase 1Unknown
- Sponsor
- HoHo Biotech
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Molecular hydrogen in autoimmune diseases, Rheumatic diseases and rheumatoid arthritis (RA) (3 arms), sponsored by HoHo Biotech. Primary endpoints: Change in Blood Routine at Day 28, Change in Urine Routine at Day 28 and 2 more. Status: unknown.
02
Drugs
Molecular hydrogen
03
Conditions
autoimmune diseasesRheumatic diseasesrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05116215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116215.